Globus Maritime Ltd(NASDAQ:GLBS) announced that Based on the reported loss for the second quarter 2012, the Company’s Board of Directors did not declare a dividend for the common shares for the six Months Ended June 30, 2012.
Additionally, the company reported second quarter revenue of $7.7 million, as compared to $7.8 million in the year ago period. Total comprehensive loss for second quarter amounted to $2.4 million versus a total comprehensive income of $1.2 million in the same quarter last year.
Thor Industries, Inc.(NYSE:THO) announced that its Board of Directors approved at its September 6, 2012 meeting, an increase in its regular quarterly dividend from $0.15 per share to $0.18 per share. The new regular dividend of $0.18 per share will be paid on October 5, 2012 to shareholders of record on September 24, 2012.
Fifth Street Finance Corp.(NASDAQ:FSC) shares climbed 2.37% to $10.69 in the pre-market hour after the company announced that it has commenced a public offering of 7,500,000 shares of its common stock. Fifth Street plans to grant the underwriters for the offering an option to purchase up to an additional 1,125,000 shares of common stock. All shares will be offered by Fifth Street. UBS Investment Bank, Goldman, Sachs & Co., J.P. Morgan and Wells Fargo Securities will act as joint book-running managers for the offering.
Talisman Energy Inc. (USA)(NYSE:TLM) stock jumped 1.40% to $14.61 in the after hour trading after the company said Chief Executive Officer John Manzoni agreed to leave. Board member Hal Kvisle has replaced him. Manzoni, who took the helm of the company in 2007, will step down immediately. Manzoni’s departure follows eight months of discussion by the board and management on ways to “rationalize the asset base.
Navidea Biopharmaceuticals Inc (NYSEAMEX:NAVB) stock plunged 35.33% to $2.27 in the after hour trading after regulators rejected its new drug application for Lymphoseek – a novel agent that has been studied in lymphatic mapping procedures performed to help stage breast cancer and melanoma. In its complete response letter, the U.S. Food and Drug Administration cited deficiencies in contract manufacturing as the reason for the Lymphoseek NDA rejection. The company is working with the FDA and contract manufacturers to address the shortcomings.